Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50820 | 0.81 | RPS6KA3 (0.49) | RPS6KA3KDM4ERPS6KA2BCAT2ALDH1A1 | |
| SCHEMBL3092115 | 0.74 | RPS6KA3 (0.42) | RPS6KA3SIGMAR1RPS6KA2ALDH1A1 | |
| SCHEMBL878127 | 0.71 | PRKCA (0.46) | PARP1HRH3KDM4EL3MBTL1SIGMAR1 | |
| SCHEMBL3088133 | 0.70 | RPS6KA3 (0.54) | RPS6KA3RPS6KA2HTR2CBCAT2 | |
| SCHEMBL3938873 | 0.67 | RPS6KA3 (0.45) | RPS6KA3KDM4EL3MBTL1RPS6KA2BCAT2 | |
| SCHEMBL895847 | 0.66 | PRKCA (0.46) | PARP1PARP2 | |
| SCHEMBL3941964 | 0.66 | RPS6KA3 (0.43) | RPS6KA3RPS6KA2 | |
| SCHEMBL3574670 | 0.65 | SRD5A2 (0.50) | RPS6KA3RPS6KA2ALDH1A1 | |
| SCHEMBL4831402 | 0.65 | RPS6KA3 (0.59) | RPS6KA3RPS6KA2 | |
| SCHEMBL3087058 | 0.65 | RPS6KA2 (0.41) | RPS6KA3SIGMAR1RPS6KA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795247-B2 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-14 | — | — | US | disclosed |
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | IDO1, ZC3HAV1, IDO2 | PARP1 807/4885RPS6KA3 1950/4885HRH3 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.